Phase II study of bevacizumab, cisplatin, and docetaxel plus maintenance bevacizumab as first-line treatment for patients with advanced non-squamous non-small-cell lung cancer combined with exploratory analysis of circulating endothelial cells: Thoracic Oncology Research Group (TORG)1016

BACKGROUND: Preclinical studies have demonstrated that docetaxel and bevacizumab may act synergistically by decreasing endothelial cell proliferation and preventing circulating endothelial progenitor mobilization. The objective of this study was to assess the efficacy and safety of a combination the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Satoshi, Kato, Terufumi, Ogura, Takashi, Sekine, Akimasa, Oda, Tsuneyuki, Masuda, Noriyuki, Igawa, Satoshi, Katono, Ken, Otani, Sakiko, Yamada, Kouzo, Saito, Haruhiro, Kondo, Tetsuro, Hosomi, Yukio, Nakahara, Yoshiro, Nishikawa, Masanori, Utumi, Keiko, Misumi, Yuki, Yamanaka, Takeharu, Sakamaki, Kentaro, Okamoto, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833040/
https://www.ncbi.nlm.nih.gov/pubmed/29499653
http://dx.doi.org/10.1186/s12885-018-4150-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833040/
https://www.ncbi.nlm.nih.gov/pubmed/29499653
http://dx.doi.org/10.1186/s12885-018-4150-y

Ejemplares similares